Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07725120
Starting soon Observational

Single-Center Study Evaluating the Impact of Age on the Diagnostic Performance of the Sural-to-Radial Sensory Amplitude Ratio in Length-Dependent and Non-Length-Dependent Peripheral Polyneuropathies

NCT07725120 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Nice
Phase
Observational
Started
2026-09-01
Last updated
2026-07-24

Condition(s) studied

PolyneuropathiesElectromyographyDiagnostic Techniques

Investigational drug(s) / intervention(s)

Retrospective Medical Record Review

Retrospective Medical Record Review: This observational study involves retrospective collection and analysis of routinely acquired clinical and electrophysiological data from approximately 180 patients with sensory polyneuropathy. Data extracted from medical records include demographic characteristics, clinical diagnosis, and nerve conduction study parameters, including sural and radial sensory nerve action potential amplitudes used to calculate the sural/radial amplitude ratio (SRAR). No additional diagnostic procedures, treatments, or study-specific assessments are performed. All data are obtained from standard clinical care.

Study summary

This retrospective single-center observational study will evaluate the impact of age on the diagnostic performance of the sural-to-radial sensory nerve amplitude ratio (SRAR) in patients with length-dependent and non-length-dependent peripheral sensory polyneuropathies. Clinical and electrophysiological data collected during routine care between January 2013 and July 2026 will be analyzed. Diagnostic performance will be assessed using receiver operating characteristic (ROC) curve analysis across predefined age groups to determine whether age-adjusted SRAR thresholds improve the differentiation between the two polyneuropathy phenotypes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years or older. * Diagnosis of peripheral sensory polyneuropathy. * Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings. * Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR. * Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026. Exclusion Criteria: * Missing or incomplete clinical or electrophysiological data preventing SRAR calculation. * Unclassifiable neuropathy phenotype. * Technical factors affecting the reliability of nerve conduction studies.

Primary outcome measure(s)

  • Diagnostic performance of the sural-to-radial sensory nerve amplitude ratio (SRAR) — Baseline (retrospective analysis of data collected between January 2013 and July 2026
    To evaluate the diagnostic performance of the SRAR for differentiating length-dependent (LDN) from non-length-dependent (NLDN) peripheral sensory polyneuropathies according to age group, using receiver operating characteristic (ROC) curve analysis.

Trial sites (1)

FacilityCityRegionStatus
CHU de Nice Nice Alpes Maritimes

More Centre Hospitalier Universitaire de Nice trials in France

Comparison of Arterial and Capillary Blood Gas Analyses in Patients With Respiratory Distress Due to COPD or APE Recruiting
METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation (HYPNOLUX) Recruiting
Upstroke Time Measured by Photoplethysmography Recruiting
Ro60 Expression in Macrophages in Sjogren's Disease Active, not recruiting
Early Functional Proprioceptive Stimulation Post-stroke Recruiting

Other trials for the same condition

Multimodal Quantified Analysis of Facial Movements: Comparison Between Pathological and Control Subjects Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07725120 on ClinicalTrials.gov ↗ ← All trials in France